Delivery Order SPE2DR25D7066-SPE2DR26F7ZNW
Award Date 12/19/25
Potential Completion Date 12/22/25
Potential Value $1.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $5,907.87 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. This firm fixed-price delivery order was awarded on November 20, 2025, with an ultimate completion date of November 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive,...
- The Defense Logistics Agency awarded a delivery order valued at $12,305.83 to AmerisourceBergen Drug Corp for Adalimumab 2PPN 2S on December 10, 2025, with an ultimate completion date of January 8, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $16,331.41 to AmerisourceBergen Drug Corp for Adalimumab 2PPN 2S, a pharmaceutical product, with performance at the contractor's Conshohocken, Pennsylvania facility. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 29, 2025, and represents a child contract under a larger indefinite delivery vehicle. The contract contains no set-aside designation, reflecting the contractor's proven...
- The Defense Logistics Agency awarded a delivery order valued at $1,953.33 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was awarded on a competitive, non-set-aside basis. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,989.95 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat various autoimmune conditions. This firm fixed-price contract, awarded November 24, 2025, with an ultimate completion date of November 25, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $9,416.16 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune and inflammatory conditions. This firm fixed price, non-set-aside delivery order was issued on November 25, 2025, with an ultimate completion date of November 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $1,193.95 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 80mg, a biologic medication used to treat Crohn's disease, ulcerative colitis, and other autoimmune conditions. The award, made on November 28, 2025, with an ultimate completion date of December 1, 2025, utilizes firm fixed-price pricing with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,102.15 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune and inflammatory conditions. This firm fixed-price delivery order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, represents a non-competitive, non-set-aside award executed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $7,091.62 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL on November 25, 2025, with an ultimate completion date of November 26, 2025. This non-set-aside contract employs firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where...